Discover the Science of Health
This week is Brain Awareness Week (BAW), an annual observance dedicated to raising public awareness about the progress and benefits of brain research. Coordinated by the Dana Alliance for Brain Initiatives and the European Dana Alliance for the Brain, every March, BAW unites the efforts of partner organizations around the world in a week-long celebration of the brain.
If there is one thing that the sugar free, low carb, low fat, and gluten free dieting trends of the past few decades have taught us, it’s this: a calorie is a calorie is a calorie. Right? Wrong! Whereas the source of the calories you consume might not have much bearing on the amount of weight you gain, when you consume them very well might. Research in both mice and humans demonstrates that eating whenever one pleases (mice) or later in the day (humans) causes significantly more weight gain than consuming the same diet in a time restricted manner, in keeping with the cyclical nature of the body’s energy metabolism.
Today is the sixth annual Rare Disease Day, an international advocacy day held on the last day of February — a rare day for rare people. On this day, millions of patients and their families from more than 60 countries and regions around the world will share their story to promote awareness of the challenges of living with a rare disease and bring widespread recognition of rare diseases as a global health challenge. This year’s slogan is “Rare Disorders without Borders”, which emphasizes the need for international cooperation.
According to new research, learning becomes more difficult as we get older because our brains get too full for new information. This may be due, in part, to finding that with advanced age we get less sleep during the stage in which we don’t dream. Both studies are reported in the prestigious Nature family of journals.
According to a new report released last month by the trade group Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical pipeline is innovative and robust, with a high percentage of potential first-in-class medicines (meaning a new treatment where nothing currently exists) targeting diseases with limited treatment options. In addition to identifying medicines in development for conditions and diseases such as septic shock, ovarian cancer, sickle cell disease, and Lou Gehrig’s disease (amyotrophic lateral sclerosis), which haven’t had any new product approvals in the last ten years, the report offers positive news for the rare disease community: one third of the products currently in clinical development have a rare disease designation by the U.S. Food and Drug Administration (FDA).
